We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Implement Diagnostics System Improves Infectious Disease Testing

By LabMedica International staff writers
Posted on 17 Dec 2019
A team of scientists recently began using machine-learning tools and assessed them in a prospective clinical trial to determine whether artificial intelligence could perform better than specialists in clinical test interpretation.

The tool automates and standardizes quantitative polymerase chain reaction (PCR) test analysis, enabling real-time monitoring on a test-by-test basis. More...
The company developed the machine-learning system in part to address shortages of trained laboratory staff, as well as to help laboratories improve internal efficiencies, both in terms of time and money saved.

Scientists from Glasgow Royal Infirmary (Glasgow, UK) undertook a prospective clinical study to evaluate the accuracy and impact when automating the manual data-analysis and quality control steps associated with routine clinical pathogen testing using real-time PCR (qPCR). They evaluated the use of the tool when used as a final interpretation and verification step for routine in-house qPCR tests for respiratory pathogens and for norovirus for a total of 22,200 interpretations. The tests were run over the course of a month. The tool is called PCR.ai and is produced by Diagnostics.ai (London, UK).

The team reported that there was 100% concurrence between validated respiratory virus and norovirus detection by their manual routine analysis method and PCR.Ai. Furthermore, there were significant routine savings with PCR.ai of 45 min/respiratory run and 32 min/norovirus run. They concluded that PCR.ai is a highly accurate time-saving tool that reduces complexity of qPCR analysis and hence the need for specialists and hands-on time. It demonstrated capabilities to enable the scientists to get results out more quickly with lower costs and less risk of errors.

Typically, the company works with a lab's existing data, which is fed to the learning machine during a training phase. Any inconsistencies are flagged and dealt with during an interactive phase. Once completed, PCR.ai is handed off to users to run in real-time on a standalone server that is not accessible to the firm. Revenues are derived via a service and support model, influenced by volumes and support needs. The firm's emphasis, however, is on reducing costs within laboratories.

Aron Cohen, BA, CEO of Diagnostics.ai, said, “The model, especially in the UK, tends to be savings driven. I think that's an important approach we have taken, that in addition to improving quality and accuracy, turnaround time, and getting better results faster, reducing costs is a vital piece of that puzzle. Some places have six- or seven-day weeks including night shifts. We need to be able to provide support for that. It's important to have the resources to be able to cope. I think taking in over 20,000 results, and proving we could do it faster, with no errors, and even picking up mistakes made in the manual process are really impressive results for any clinical or AI product.” The study was published in the November, 2019 issue of the Journal of Clinical Virology.

Related Links:
Glasgow Royal Infirmary
Diagnostics.ai


New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Online QC Software
Acusera 24•7
Benchtop Thermomixer
Biometra TS1 ThermoShaker
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
An overview of the study and findings: A) Several brain-derived EVPs cross the blood brain barrier and reach circulation. B) Different EVPs enrich different RNA cargo B) The EVP-RNA is impacted, upregulated (green) or downregulated (red) in AD (Gonzalez-Kozlova, E., et al., Nature Communications (2026). doi.org/10.1038/s41467-026-74541-8)

RNA Blood Test May Enable Earlier Alzheimer’s Disease Diagnosis

Alzheimer’s disease affects an estimated 55 million people worldwide and remains difficult to diagnose at an early stage. Diagnostic workups can be complicated by symptom overlap with other conditions,... Read more

Microbiology

view channel
Image: Multidrug-resistant Klebsiella pneumoniae is a growing community health concern, causing recurrent UTIs in older adults and complicating first-line antibiotic treatment (Image Credit: Adobe Stock)

Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella

Multidrug-resistant Klebsiella pneumoniae is an escalating community health concern, driving recurrent urinary tract infections in older adults and complicating first-line antibiotic therapy.... Read more

Industry

view channel
Image

QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools

QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.